215 related articles for article (PubMed ID: 38472477)
1. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
McLornan DP; Czerw T; Damaj G; Ethell M; Gurnari C; Hernández-Boluda JC; Polverelli N; Schwaab J; Sockel K; Raffaella G; Onida F; Sánchez-Ortega I; Battipaglia G; Elena C; Gotlib J; Reiter A; Rossignol J; Ustun C; Valent P; Yakoub-Agha I; Radia DH
Leukemia; 2024 Apr; 38(4):699-711. PubMed ID: 38472477
[TBL] [Abstract][Full Text] [Related]
2. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
3. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Pardanani A; Reichard K; Tefferi A
Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
[TBL] [Abstract][Full Text] [Related]
4. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
[TBL] [Abstract][Full Text] [Related]
6. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
7. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
8. Precision Medicine in Systemic Mastocytosis.
Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
Lübke J; Christen D; Schwaab J; Kaiser A; Naumann N; Shoumariyeh K; Jentzsch M; Sockel K; Schaffrath J; Ayuk FA; Stelljes M; Hilgendorf I; Sala E; Kaivers J; Schönland S; Wittke C; Hertenstein B; Radsak M; Kaiser U; Brückl V; Kröger N; Brümmendorf TH; Hofmann WK; Klein S; Jost E; Reiter A; Panse J
Leukemia; 2024 Apr; 38(4):810-821. PubMed ID: 38448757
[TBL] [Abstract][Full Text] [Related]
10. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract][Full Text] [Related]
13. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
14. Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.
Sriskandarajah P; McLornan DP; Oni C; Wilson AJ; Woodley C; Ciesielska M; Raj K; Dillon R; Ethell M; Chacko J; Orchard K; Radia DH
Curr Res Transl Med; 2023; 71(3):103398. PubMed ID: 37331225
[TBL] [Abstract][Full Text] [Related]
15. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
[TBL] [Abstract][Full Text] [Related]
17. The new tool "
Shomali W; Gotlib J
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]